Sailong Pharmaceutical Group Co., Ltd.
SZSE:002898.SZ
12.44 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 263.567 | 310.627 | 264.193 | 247.079 | 120.684 | 293.467 | 436.273 | 364.219 | 255.837 | 237.495 | 178.094 | 221.342 |
| Cost of Revenue
| 162.746 | 171.108 | 122.94 | 83.464 | 43.307 | 75.559 | 188.807 | 159.804 | 115.193 | 102.454 | 78.793 | 89.261 |
| Gross Profit
| 100.821 | 139.519 | 141.253 | 163.615 | 77.377 | 217.908 | 247.465 | 204.414 | 140.644 | 135.041 | 99.3 | 132.081 |
| Gross Profit Ratio
| 0.383 | 0.449 | 0.535 | 0.662 | 0.641 | 0.743 | 0.567 | 0.561 | 0.55 | 0.569 | 0.558 | 0.597 |
| Reseach & Development Expenses
| 24.512 | 27.529 | 23.501 | 21.412 | 25.673 | 17.582 | 16.238 | 3.998 | 4.463 | 4.965 | 1.938 | 0 |
| General & Administrative Expenses
| 18.043 | 19.462 | 13.714 | 13.715 | 23.225 | 11.399 | 9.81 | 15.308 | 12.339 | 14.951 | 34.562 | 32.521 |
| Selling & Marketing Expenses
| 21.141 | 57.15 | 98.703 | 113.466 | 74.553 | 134.651 | 126.034 | 72.636 | 19.45 | 17.541 | 14.878 | 14.766 |
| SG&A
| 39.184 | 95.408 | 112.417 | 127.181 | 97.778 | 146.05 | 135.844 | 87.944 | 31.789 | 32.492 | 49.44 | 47.288 |
| Other Expenses
| 72.543 | -5.985 | 29.293 | 27.96 | 25.887 | 20.914 | -2.402 | -1.926 | 2.818 | 11.696 | 4.262 | 0.978 |
| Operating Expenses
| 136.239 | 116.952 | 165.211 | 176.552 | 149.338 | 184.545 | 174.17 | 127.51 | 71.464 | 65.935 | 71.372 | 49.95 |
| Operating Income
| -35.417 | 22.567 | -6.556 | 3.337 | -71.961 | 32.491 | 70.191 | 76.807 | 66.337 | 69.323 | 27.454 | 64.641 |
| Operating Income Ratio
| -0.134 | 0.073 | -0.025 | 0.014 | -0.596 | 0.111 | 0.161 | 0.211 | 0.259 | 0.292 | 0.154 | 0.292 |
| Total Other Income Expenses Net
| 0.498 | -0.21 | -0.881 | -17.107 | -1.839 | -0.264 | -0.19 | -0.456 | 4.354 | 12.18 | 4.018 | 0.978 |
| Income Before Tax
| -34.92 | 22.357 | -29.671 | -13.769 | -48.826 | 32.226 | 70.001 | 76.481 | 70.689 | 81.503 | 31.472 | 65.62 |
| Income Before Tax Ratio
| -0.132 | 0.072 | -0.112 | -0.056 | -0.405 | 0.11 | 0.16 | 0.21 | 0.276 | 0.343 | 0.177 | 0.296 |
| Income Tax Expense
| -1.774 | 12.823 | 7.642 | 9.572 | 18.396 | 4.743 | 9.096 | 11.976 | 9.44 | 18.185 | 3.281 | 19.742 |
| Net Income
| -33.146 | 9.534 | -37.312 | -23.341 | -67.222 | 27.483 | 60.905 | 64.505 | 61.249 | 63.318 | 28.191 | 45.877 |
| Net Income Ratio
| -0.126 | 0.031 | -0.141 | -0.094 | -0.557 | 0.094 | 0.14 | 0.177 | 0.239 | 0.267 | 0.158 | 0.207 |
| EPS
| -0.19 | 0.054 | -0.21 | -0.13 | -0.38 | 0.16 | 0.35 | 0.45 | 0.46 | 0.5 | 0.24 | 0.39 |
| EPS Diluted
| -0.19 | 0.054 | -0.21 | -0.13 | -0.38 | 0.16 | 0.35 | 0.45 | 0.46 | 0.5 | 0.24 | 0.39 |
| EBITDA
| 6.053 | 62.099 | 12.55 | 25.699 | -13.436 | 54.007 | 84.443 | 87.087 | 78.958 | 87.924 | 37.624 | 86.416 |
| EBITDA Ratio
| 0.023 | 0.2 | 0.048 | 0.104 | -0.111 | 0.184 | 0.194 | 0.239 | 0.309 | 0.37 | 0.211 | 0.39 |